A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

This study is for patients aged 18 and older, both male and female, who have a specific type of blood cancer.

The cancer must be Acute Lymphoblastic Leukemia (ALL) that is either Philadelphia chromosome-positive (Ph+) or Ph-like. It's important that your cancer has either come back after previous treatment or has not responded to other treatments you've had.

There will be other detailed medical checks to make sure this study is right and safe for you, which your doctor will discuss. Currently, the age range starts from 18 years, so children and younger teenagers are not eligible for this specific trial.

If you decide to take part, you will receive a combination of medicines including asciminib, chemotherapy drugs (like cytarabine, methotrexate, vincristine sulfate), steroids (like hydrocortisone, prednisolone acetate, dexamethasone), and blinatumomab. These will be given in cycles, meaning you'll have periods of treatment followed by rest periods.

Throughout the study, you'll have regular hospital visits for assessments. These will involve blood tests to check how you're responding to the treatment and to monitor for any side effects. You'll also have scans or other tests to look at the cancer. The first part of the study will involve closely monitoring side effects during the first treatment cycle to find the safest dose. The second part will focus on how many people's cancer goes into remission after the first cycle. The total duration of your participation will depend on how you respond to the treatment and the study’s protocol, but it will involve follow-up appointments after the main treatment period.